Brief: Scynexis Presents Positive Data From Its Pivotal Phase 3 Candle Study Of Oral Ibrexafungerp For Prevention Of Recurrent Vaginal Yeast Infections During 2022 Idsog Annual Meeting

Scynexis

04/08/2022 17:28

Aug 4 (Reuters) - SCYNEXIS Inc  SCYX.O :
    * SCYNEXIS PRESENTS POSITIVE DATA FROM ITS PIVOTAL PHASE 3
CANDLE
STUDY OF ORAL IBREXAFUNGERP FOR PREVENTION OF RECURRENT VAGINAL
YEAST INFECTIONS DURING THE 2022 IDSOG ANNUAL MEETING
    * SCYNEXIS INC- IN STUDY, IBREXAFUNGERP WAS GENERALLY SAFE
AND
WELL-TOLERATED
    * SCYNEXIS INC- IN STUDY, NO SERIOUS DRUG-RELATED ADVERSE
EVENTS, 
NO PATIENTS TREATED WITH IBREXAFUNGERP DISCONTINUED THERAPY DUE
TO ADVERSE EVENTS
    * SCYNEXIS- STUDY MET PRIMARY ENDPOINT, WITH 65.4% OF
PATIENTS WHO
GOT MONTHLY SINGLE-DAY IBREXAFUNGERP TREATMENT ACHIEVING
CLINICAL SUCCESS WITH NO RECURRENCE

Source text for Eikon:  GNX6kFd6L 
Further company coverage:  SCYX.O 

 ((Reuters.Briefs@thomsonreuters.com;))